Sab Biotherapeutics (SABS) | Stock Overview & Key Data
Sab Biotherapeutics Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $129.00 on October 18, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sab Biotherapeutics
SABS
|
247.37M Micro-cap | -8.66% | -5.69% | -14.50% | -4.40% | -7.69% | 86.53% | -60.74% | -96.35% | -96.47% | -96.47% | -96.47% |
|
Vertex
VRTX
|
109.45B Large-cap | -2.49% | -1.11% | -12.54% | -1.86% | -5.98% | 1.24% | 34.08% | 113.19% | 376.31% | 717.28% | 1,190.86% |
|
Regeneron
REGN
|
80.98B Large-cap | -5.03% | -15.02% | -23.79% | -18.77% | -22.36% | 25.39% | -16.92% | 20.10% | 53.41% | 959.24% | 4,557.42% |
|
Adagene
ADAG
|
243.81M Micro-cap | -8.87% | -7.38% | 14.53% | 70.35% | 84.24% | 104.64% | 198.50% | -71.19% | -85.65% | -85.65% | -85.65% |
|
Orchestra BioMed
OBIO
|
242.86M Micro-cap | -1.76% | -2.99% | -10.96% | -18.24% | -9.51% | 37.19% | -75.14% | -61.44% | -51.73% | -51.73% | -51.73% |
|
Third Harmonic Bio
THRD
|
242.79M Micro-cap | 0.00% | -1.28% | 4.47% | 56.40% | 56.40% | -53.82% | -70.11% | -70.11% | -70.11% | -70.11% | -70.11% |
Ownership & Short Interest
Calculate Your Sab Biotherapeutics Investment Returns
Long-Term Investment Performance Analysis
Sab Biotherapeutics stock price in Feb 2021 was $102.10, A $1,000.00 lump sum investment in Sab Biotherapeutics made 5 years ago would be worth approximately $33.01 today, representing a negative return of -96.70%. This translates to an annualized return (CAGR) of -47.37%.
5 Years 3 Months Investment Scenario (Feb 2021 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is SABS's 52-week high and low?
- In the last 52 weeks, Sab Biotherapeutics reached a high of $6.60 (on July 21, 2025) and a low of $1.60 (on June 13, 2025).
- What is the market cap and P/E ratio for SABS?
- Curious about Sab Biotherapeutics's size and valuation? Its market capitalization stands at 247.37M. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is -10.67.
- Does SABS pay dividends? If so, what's the yield?
- As for dividends, Sab Biotherapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Sab Biotherapeutics's main competitors or similar companies to consider before investing?
When looking at Sab Biotherapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology 1.24% 34.08% Regeneron
REGN80.98B Healthcare Biotechnology 25.39% -16.92% Adagene
ADAG243.81M Healthcare Biotechnology 104.64% 198.50% Orchestra BioMed
OBIO242.86M Healthcare Biotechnology 37.19% -75.14% Third Harmonic Bio
THRD242.79M Healthcare Biotechnology -53.82% -70.11% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Sab Biotherapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Sab Biotherapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 14.96%, the Debt to Equity ratio from the most recent quarter is 3.93, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for SABS?
- Looking at Sab Biotherapeutics's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of SABS stock is held by insiders and institutions?
- Wondering who owns Sab Biotherapeutics stock? Company insiders (like executives and directors) hold about 0.96% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 58.73%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.